Yung‐Jue Bang
About
Yung‐Jue Bang is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology.
According to data from OpenAlex, Yung‐Jue Bang has authored 610 papers receiving a total of 37.1k indexed citations (citations by other indexed papers that have themselves been cited), including 438 papers in Oncology, 311 papers in Pulmonary and Respiratory Medicine and 153 papers in Molecular Biology. Recurrent topics in Yung‐Jue Bang's work include Gastric Cancer Management and Outcomes (210 papers), Colorectal Cancer Treatments and Studies (135 papers) and Lung Cancer Treatments and Mutations (94 papers). Yung‐Jue Bang is often cited by papers focused on Gastric Cancer Management and Outcomes (210 papers), Colorectal Cancer Treatments and Studies (135 papers) and Lung Cancer Treatments and Mutations (94 papers). Yung‐Jue Bang collaborates with scholars based in South Korea, United States and Japan. Yung‐Jue Bang's co-authors include Do‐Youn Oh, Hyun Cheol Chung, Seock‐Ah Im, Eric Van Cutsem, Sae‐Won Han, Florian Lordick, Yoon‐Koo Kang, Atsushi Ohtsu, Taroh Satoh and Julie Hill and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.
In The Last Decade
Yung‐Jue Bang
600 papers receiving 36.4k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Yung‐Jue Bang South Korea | 87 | 20.9k | 17.1k | 10.8k | 7.6k | 4.6k | 610 | 37.1k | ||
| Hyun Cheol Chung South Korea | 64 | 15.2k 0.7× | 14.1k 0.8× | 5.7k 0.5× | 7.2k 0.9× | 3.4k 0.7× | 603 | 27.8k | ||
| Heikki Joensuu Finland | 97 | 12.8k 0.6× | 12.6k 0.7× | 8.4k 0.8× | 7.1k 0.9× | 6.2k 1.4× | 583 | 35.5k | ||
| Jaffer A. Ajani United States | 101 | 16.8k 0.8× | 26.9k 1.6× | 8.8k 0.8× | 21.2k 2.8× | 4.6k 1.0× | 939 | 45.2k | ||
| Josep Tabernero Spain | 102 | 34.3k 1.6× | 14.7k 0.9× | 14.4k 1.3× | 8.1k 1.1× | 8.9k 1.9× | 1.1k | 50.8k | ||
| Andrés Cervantes Spain | 68 | 18.1k 0.9× | 9.4k 0.6× | 4.2k 0.4× | 8.4k 1.1× | 3.3k 0.7× | 468 | 27.8k | ||
| Samuel Singer United States | 90 | 8.1k 0.4× | 16.7k 1.0× | 7.3k 0.7× | 4.9k 0.6× | 3.1k 0.7× | 331 | 28.9k | ||
| Ian Judson United Kingdom | 79 | 10.8k 0.5× | 16.5k 1.0× | 6.0k 0.6× | 5.0k 0.7× | 2.4k 0.5× | 403 | 28.0k | ||
| Atsushi Ohtsu Japan | 75 | 14.2k 0.7× | 17.2k 1.0× | 4.8k 0.4× | 9.9k 1.3× | 2.0k 0.4× | 526 | 26.9k | ||
| Atsushi Ochiai Japan | 82 | 11.2k 0.5× | 7.8k 0.5× | 8.9k 0.8× | 5.2k 0.7× | 4.2k 0.9× | 594 | 25.1k | ||
| George D. Demetri United States | 93 | 11.1k 0.5× | 23.7k 1.4× | 6.6k 0.6× | 8.9k 1.2× | 3.7k 0.8× | 346 | 38.0k |
Countries citing papers authored by Yung‐Jue Bang
Since
Specialization
Citations
This map shows the geographic impact of Yung‐Jue Bang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yung‐Jue Bang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yung‐Jue Bang more than expected).
Fields of papers citing papers by Yung‐Jue Bang
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Yung‐Jue Bang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yung‐Jue Bang. The network helps show where Yung‐Jue Bang may publish in the future.
Co-authorship network of co-authors of Yung‐Jue Bang
This figure shows the co-authorship network connecting the top 25 collaborators of Yung‐Jue Bang. A scholar is included among the top collaborators of Yung‐Jue Bang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yung‐Jue Bang. Yung‐Jue Bang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Harding, James J., Víctor Moreno, Yung‐Jue Bang, et al.. (2021). Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody. Clinical Cancer Research. 27(8). 2168–2178.
2.
Chung, Hyun Cheol, Yung‐Jue Bang, Charles S. Fuchs, et al.. (2020). First-Line Pembrolizumab/Placebo Plus Trastuzumab and Chemotherapy in Her2-Positive Advanced Gastric Cancer: KEYNOTE-811. Future Oncology. 17(5). 491–501.
3.
Shitara, Kohei, Yung‐Jue Bang, Satoru Iwasa, et al.. (2020). Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. New England Journal of Medicine. 382(25). 2419–2430.
4.
Lee, Hyun A., Hyun A. Lee, Do‐Youn Oh, et al.. (2020). A target‐mediated drug disposition population pharmacokinetic model of GC1118, a novel anti‐EGFR antibody, in patients with solid tumors. Clinical and Translational Science. 14(3). 990–1001.
5.
Kang, Yoon‐Koo, Yung‐Jue Bang, Shunsuke Kondo, et al.. (2020). Safety and Tolerability of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Asian Patients with Pretreated Recurrent or Refractory Gastric Cancer. Clinical Cancer Research. 26(13). 3202–3210.
6.
Patnaik, Amita, Timothy A. Yap, Hyun Cheol Chung, et al.. (2020). Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial. Clinical Cancer Research. 27(5). 1267–1277.
7.
Oh, Do‐Youn & Yung‐Jue Bang. (2019). HER2-targeted therapies — a role beyond breast cancer. Nature Reviews Clinical Oncology. 17(1). 33–48.
8.
Ott, Patrick A., Yung‐Jue Bang, Dominique Berton-Rigaud, et al.. (2017). Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1–Positive Endometrial Cancer: Results From the KEYNOTE-028 Study. Journal of Clinical Oncology. 35(22). 2535–2541.
9.
Bang, Yung‐Jue, Y. Choi, Yeul Hong Kim, et al.. (2017). Efficacy of Sequential Ipilimumab Monotherapy versus Best Supportive Care for Unresectable Locally Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer. Clinical Cancer Research. 23(19). 5671–5678.
10.
An, Eunkyung, Chan‐Young Ock, T.-Y. Kim, et al.. (2016). Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment. Annals of Oncology. 28(1). 110–115.
11.
Shah, Manish A., Yung‐Jue Bang, Florian Lordick, et al.. (2016). Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma. JAMA Oncology. 3(5). 620–620.
12.
Satoh, Taroh, Rui‐Hua Xu, Hyun Cheol Chung, et al.. (2014). Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of HER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study. Journal of Clinical Oncology. 32(19). 2039–2049.
13.
Kwon, Jeanny, Eui Kyu Chie, Kyubo Kim, et al.. (2014). Impact of Multimodality Approach for Patients with Leptomeningeal Metastases from Solid Tumors. Journal of Korean Medical Science. 29(8). 1094–1094.
14.
Han, Sae‐Won, Hwang-Phill Kim, Jong-Yeon Shin, et al.. (2013). Targeted Sequencing of Cancer-Related Genes in Colorectal Cancer Using Next-Generation Sequencing. PLoS ONE. 8(5). e64271–e64271.
15.
Min, Ahrum, Seock‐Ah Im, Young‐Kwang Yoon, et al.. (2013). RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib. Molecular Cancer Therapeutics. 12(6). 865–877.
16.
Vinik, Aaron I., Eric Van Cutsem, Patricia Niccoli, et al.. (2012). Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) and Updated Overall Survival (OS) of Sunitinib versus Placebo for Patients with Progressive, Unresectable, Well Differentiated Pancreatic Neuroendocrine Tumor (NET). Pancreas. 41(2). 350–350.
17.
Im, Seock‐Ah, Jin Won Kim, Jin-Soo Kim, et al.. (2011). Clinicopathologic Characteristics of Patients With Stage III/IV (M0) Advanced Gastric Cancer, According to HER2 Status Assessed by Immunohistochemistry and Fluorescence In Situ Hybridization. Diagnostic Molecular Pathology. 20(2). 94–100.
18.
Bang, Yung‐Jue, Eric Van Cutsem, A. Feyereislova, et al.. (2010). Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. The Lancet. 376(9742). 687–697.
19.
Kim, Yu Jung, Min A Kim, Seock‐Ah Im, et al.. (2008). Metastasis-Associated Protein S100A4 and p53 Predict Relapse in Curatively Resected Stage III and IV (M0) Gastric Cancer. Cancer Investigation. 26(2). 152–158.
20.
Han, Sae‐Won, Tae‐You Kim, Yoon Kyung Jeon, et al.. (2006). Optimization of Patient Selection for Gefitinib in Non–Small Cell Lung Cancer by Combined Analysis of Epidermal Growth Factor Receptor Mutation, K-ras Mutation, and Akt Phosphorylation. Clinical Cancer Research. 12(8). 2538–2544.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Hyun Cheol Chung Breakdown of academic impact, for papers by Heikki Joensuu Breakdown of academic impact, for papers by Jaffer A. Ajani Breakdown of academic impact, for papers by Josep Tabernero Breakdown of academic impact, for papers by Andrés Cervantes Breakdown of academic impact, for papers by Samuel Singer Breakdown of academic impact, for papers by Ian Judson Breakdown of academic impact, for papers by Atsushi Ohtsu Breakdown of academic impact, for papers by Atsushi Ochiai Breakdown of academic impact, for papers by George D. Demetri